Shailendra Dwivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shailendra Dwivedi has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Sanjeev Misra
Atal Bihari Bajpayee Medical University, Lucknow, 225001, India; and All India Institute of Medical Sciences Jodhpur, 243005, India
12 shared publicationsRuchika Agrawal
Department of E.N.T, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India
10 shared publications- Praveen Sharma
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, India
8 shared publications Akash Bansal
Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India
6 shared publications- Apul Goel
Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India
6 shared publications Kamlesh Kumar Pant
Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India
6 shared publications
Latest Publications
- 12 October 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22, 1-19
Chronotherapeutic and Circadian Rhythm-Based Strategies in Diabetes Management: A Critical Opinion Based on Evidences
Diabetes mellitus is one of the world’s leading health problems, and standard approaches to therapy do not take into consideration the impact of circadian misalignment on metabolic health. Chronobiological processes are involved in regulating glucose homeostasis, insulin release, hepatic glucose production, lipids, and energy metabolism; hence, disruptions such as those caused by non-rhythmic sleep patterns, shifts at work, irregular meal times, and light exposure could cause insulin resistance and even type 2 diabetes. The current critical review discusses the light-melatonin interaction and personalized chronobiological medicine. Instead of giving a descriptive account of particular treatments, the paper introduces the integrative importance of chronobiology for the management of diabetes by considering data about chrononutrition, time-restricted feeding, chronopharmacology, chrono-exercise, and an approach to chronometabolism based on the integration of the timing of meals, drugs, exercise, sleep, and light exposure with chronotype, metabolic phenotype, and the feasibility of the therapy. Circadian timing can be a promising adjuvant in the treatment of diabetes; however, the available evidence does not suggest an ideal time for intervention. Further studies should focus on measuring time, well-powered randomized controlled trials, long-term outcomes, and individualization of chronotherapy.
- 12 October 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22, 1-19
Chronotherapeutic and Circadian Rhythm-Based Strategies in Diabetes Management: A Critical Opinion Based on Evidences
Diabetes mellitus is one of the world’s leading health problems, and standard approaches to therapy do not take into consideration the impact of circadian misalignment on metabolic health. Chronobiological processes are involved in regulating glucose homeostasis, insulin release, hepatic glucose production, lipids, and energy metabolism; hence, disruptions such as those caused by non-rhythmic sleep patterns, shifts at work, irregular meal times, and light exposure could cause insulin resistance and even type 2 diabetes. The current critical review discusses the light-melatonin interaction and personalized chronobiological medicine. Instead of giving a descriptive account of particular treatments, the paper introduces the integrative importance of chronobiology for the management of diabetes by considering data about chrononutrition, time-restricted feeding, chronopharmacology, chrono-exercise, and an approach to chronometabolism based on the integration of the timing of meals, drugs, exercise, sleep, and light exposure with chronotype, metabolic phenotype, and the feasibility of the therapy. Circadian timing can be a promising adjuvant in the treatment of diabetes; however, the available evidence does not suggest an ideal time for intervention. Further studies should focus on measuring time, well-powered randomized controlled trials, long-term outcomes, and individualization of chronotherapy.
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 25, 1-13
The Gut Microbiota–inflammation–immune Axis in Cancer: Anti-inflammatory Mechanisms and Therapeutic Implications
Through its mediation between inflammatory and immune pathways, the gut microbiota has proved to be a key regulator of cancer development, progression, and treatment response. Changes in microbial composition known as dysbiosis might facilitate chronic inflammation, immune dysregulation, and genomic instability, thereby facilitating carcinogenesis. Conversely, positive commensal microbes can generate short-chain fatty acids, bile acids, and tryptophan derivatives, which help maintain the epithelial barrier, cytokine signaling, and innate and adaptive immune responses. These microbial metabolites regulate immune cell differentiation, including regulatory T cells, dendritic cells, macrophages, and cytotoxic CD8+ T cells, thereby impacting the tumor microenvironment and tumor progression. Recent research highlights the microbiota as an outcome of response to cancer therapies, particularly immune checkpoint inhibitors, chemotherapy, and targeted therapies. Certain microbial genera, e.g., Akkermansia muciniphila, Bifidobacterium species, and Faecalibacterium prausnitzii, have been linked to augmented antitumor immunity and treatment efficacy. To enhance treatment outcomes and minimize toxicity during therapy, therapeutic interventions that target the regulation of the gut microbiome, such as dietary interventions, probiotics, prebiotics, fecal microbiota transplantation, and engineered microbial platforms, are under investigation. Moreover, improvements in metagenomics, metabolomics, and immunomics are now enabling the discovery of microbiome-based biomarkers to inform precision oncology. Knowledge of the gut microbiota–inflammation–immune axis thus presents promising possibilities in creating new treatment modalities and in designing individualized treatments in cancer management.
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 25, 1-13
The Gut Microbiota–inflammation–immune Axis in Cancer: Anti-inflammatory Mechanisms and Therapeutic Implications
Through its mediation between inflammatory and immune pathways, the gut microbiota has proved to be a key regulator of cancer development, progression, and treatment response. Changes in microbial composition known as dysbiosis might facilitate chronic inflammation, immune dysregulation, and genomic instability, thereby facilitating carcinogenesis. Conversely, positive commensal microbes can generate short-chain fatty acids, bile acids, and tryptophan derivatives, which help maintain the epithelial barrier, cytokine signaling, and innate and adaptive immune responses. These microbial metabolites regulate immune cell differentiation, including regulatory T cells, dendritic cells, macrophages, and cytotoxic CD8+ T cells, thereby impacting the tumor microenvironment and tumor progression. Recent research highlights the microbiota as an outcome of response to cancer therapies, particularly immune checkpoint inhibitors, chemotherapy, and targeted therapies. Certain microbial genera, e.g., Akkermansia muciniphila, Bifidobacterium species, and Faecalibacterium prausnitzii, have been linked to augmented antitumor immunity and treatment efficacy. To enhance treatment outcomes and minimize toxicity during therapy, therapeutic interventions that target the regulation of the gut microbiome, such as dietary interventions, probiotics, prebiotics, fecal microbiota transplantation, and engineered microbial platforms, are under investigation. Moreover, improvements in metagenomics, metabolomics, and immunomics are now enabling the discovery of microbiome-based biomarkers to inform precision oncology. Knowledge of the gut microbiota–inflammation–immune axis thus presents promising possibilities in creating new treatment modalities and in designing individualized treatments in cancer management.
- 1 October 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 27 (10) , 3747-3754
Tobacco-Associated Dysregulation in TAP-1 and TAP-2 Expression in Oral Premalignant Lesions and Oral Squamous Cell Carcinoma
Background: TAP-1, and TAP-2 are required for MHC class I–restricted antigen surveillance. Downregulated TAP expression in oral carcinogenesis might affect the antigen presentation system, leading to immune evasion. Tobacco is the most common aetiologic risk factor for Oral Squamous Cell Cancer, and it could influence antigen-processing mechanisms throughout the stages of Oral Squamous Cell Cancer. Materials and Methods: This hospital-based case-control study included 60 cases of oral squamous cell carcinoma (OSCC), 60 oral premalignant lesions, and 60 age and sex-matched healthy controls. A standardised questionnaire was used to collect information about tobacco exposure patterns. Before beginning treatment, peripheral blood samples were taken. Total RNA was extracted and reverse-transcribed, and TAP-1 and TAP-2 gene expression was measured using SYBR Green-based real-time PCR, with relative gene expression calculated using the 2-ΔΔCt method with normalization to the housekeeping gene. Non-parametric tests and multivariate linear regression was used for statistical analysis. Results: Combined tobacco users were most common among OSCC (50–55%), with about 88.3% of controls being non-users. TAP-1 expression demonstrated a significant decrease in leukoplakia smokeless tobacco-related (mean = 0.80; p = 0.048), and with the OSCC dedifferentiation, which was even lower in poorly differentiated tumours (mean = 0.68; p = 0.029). Expression of TAP-2 was not altered in premalignant conditions, whereas it was remarkably decreased in OSCC patients with mixed tobacco habit (mean = 0.85; p = 0.044). Multivariate analysis revealed an independent effect of mixed tobacco on lower TAP expression, as well as a role for grade (p < 0.05). Conclusion: Simultaneous tobacco exposure induces a modest but significant decline in TAP-2 with differentiation-dependent reduction of TAP-1, suggesting that the subtle dysfunction in antigen processing machinery during oral carcinogenesis.
- 1 October 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 27 (10) , 3747-3754
Tobacco-Associated Dysregulation in TAP-1 and TAP-2 Expression in Oral Premalignant Lesions and Oral Squamous Cell Carcinoma
Background: TAP-1, and TAP-2 are required for MHC class I–restricted antigen surveillance. Downregulated TAP expression in oral carcinogenesis might affect the antigen presentation system, leading to immune evasion. Tobacco is the most common aetiologic risk factor for Oral Squamous Cell Cancer, and it could influence antigen-processing mechanisms throughout the stages of Oral Squamous Cell Cancer. Materials and Methods: This hospital-based case-control study included 60 cases of oral squamous cell carcinoma (OSCC), 60 oral premalignant lesions, and 60 age and sex-matched healthy controls. A standardised questionnaire was used to collect information about tobacco exposure patterns. Before beginning treatment, peripheral blood samples were taken. Total RNA was extracted and reverse-transcribed, and TAP-1 and TAP-2 gene expression was measured using SYBR Green-based real-time PCR, with relative gene expression calculated using the 2-ΔΔCt method with normalization to the housekeeping gene. Non-parametric tests and multivariate linear regression was used for statistical analysis. Results: Combined tobacco users were most common among OSCC (50–55%), with about 88.3% of controls being non-users. TAP-1 expression demonstrated a significant decrease in leukoplakia smokeless tobacco-related (mean = 0.80; p = 0.048), and with the OSCC dedifferentiation, which was even lower in poorly differentiated tumours (mean = 0.68; p = 0.029). Expression of TAP-2 was not altered in premalignant conditions, whereas it was remarkably decreased in OSCC patients with mixed tobacco habit (mean = 0.85; p = 0.044). Multivariate analysis revealed an independent effect of mixed tobacco on lower TAP expression, as well as a role for grade (p < 0.05). Conclusion: Simultaneous tobacco exposure induces a modest but significant decline in TAP-2 with differentiation-dependent reduction of TAP-1, suggesting that the subtle dysfunction in antigen processing machinery during oral carcinogenesis.
- Open Access
- 1 June 2026
- Published by KEAI Publishing in Journal of Biosafety and Biosecurity
- Vol. 8 (2) , 111-117
Regulating synthetic biology and advanced genetic interventions: biosecurity frameworks, gene therapy oversight, stem-cell manufacturing risks and future policy directions
- 1 June 2026
- Published by KEAI Publishing in Journal of Biosafety and Biosecurity
- Vol. 8 (2) , 111-117
Open AccessRegulating synthetic biology and advanced genetic interventions: biosecurity frameworks, gene therapy oversight, stem-cell manufacturing risks and future policy directions
- Open Access
- 1 January 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 27 (1) , 381-388
NF-κB (p65, p50), IL-18, and IL-10 as Therapeutic Targets in Prostate Cancer and BPH: Molecular Insights into Inflammation-Driven Pathogenesis
Background: Prostate cancer is a significant global health burden and is the second most commonly diagnosed malignancy among men. Chronic inflammation and environmental exposures, including occupational toxins, are increasingly recognized as key contributors to its development. Nuclear factor kappa B (NF-κB) subunits p65 and p50, along with the cytokines IL-18 and IL-10, are central mediators of inflammation, but remain understudied in the context of benign prostatic hyperplasia (BPH) and occupation-related risks. This study investigates the expression patterns of these markers in prostate cancer, BPH, and healthy individuals, and examines their association with disease stage and occupational exposure. Methods: A total of 664 participants were enrolled, including 285 prostate cancer patients, 94 BPH cases, and 285 healthy controls. Peripheral blood samples were collected and analyzed for mRNA expression using quantitative real-time PCR (qRT-PCR), and for protein levels using ELISA. Statistical comparisons among groups and two-way ANOVA were performed to evaluate the effects of disease status and occupation. Correlation analysis was used to assess the associations between NF-κB and cytokine levels. Results: NF-κB p65 and p50, as well as IL-18 and IL-10, were significantly upregulated in prostate cancer compared to BPH and controls (p < 0.0001). Expression levels increased with cancer stage and metastatic status. Among occupational groups, tannery workers exhibited the highest biomarker expression. Significant positive correlations were found between NF-κB subunits and both cytokines. Conclusion: NF-κB and its downstream cytokines, IL-18 and IL-10, may serve as inflammation-driven, noninvasive biomarkers for prostate cancer diagnosis, staging, and risk stratification, particularly in populations exposed to environmental factors.
- 1 January 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 27 (1) , 381-388
Open AccessNF-κB (p65, p50), IL-18, and IL-10 as Therapeutic Targets in Prostate Cancer and BPH: Molecular Insights into Inflammation-Driven Pathogenesis
Background: Prostate cancer is a significant global health burden and is the second most commonly diagnosed malignancy among men. Chronic inflammation and environmental exposures, including occupational toxins, are increasingly recognized as key contributors to its development. Nuclear factor kappa B (NF-κB) subunits p65 and p50, along with the cytokines IL-18 and IL-10, are central mediators of inflammation, but remain understudied in the context of benign prostatic hyperplasia (BPH) and occupation-related risks. This study investigates the expression patterns of these markers in prostate cancer, BPH, and healthy individuals, and examines their association with disease stage and occupational exposure. Methods: A total of 664 participants were enrolled, including 285 prostate cancer patients, 94 BPH cases, and 285 healthy controls. Peripheral blood samples were collected and analyzed for mRNA expression using quantitative real-time PCR (qRT-PCR), and for protein levels using ELISA. Statistical comparisons among groups and two-way ANOVA were performed to evaluate the effects of disease status and occupation. Correlation analysis was used to assess the associations between NF-κB and cytokine levels. Results: NF-κB p65 and p50, as well as IL-18 and IL-10, were significantly upregulated in prostate cancer compared to BPH and controls (p < 0.0001). Expression levels increased with cancer stage and metastatic status. Among occupational groups, tannery workers exhibited the highest biomarker expression. Significant positive correlations were found between NF-κB subunits and both cytokines. Conclusion: NF-κB and its downstream cytokines, IL-18 and IL-10, may serve as inflammation-driven, noninvasive biomarkers for prostate cancer diagnosis, staging, and risk stratification, particularly in populations exposed to environmental factors.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (1) , 53-66
Gene Therapy and Gene Editing: Current Trends and Future Prospects of Molecular Medicine
Gene therapy and genome editing have emerged as transformative approaches in the management of a diverse range of genetic and acquired diseases. This evaluation offers a thorough examination of the present state and prospects of these innovative technologies. Gene therapy is a prospective approach to the treatment and prevention of a variety of conditions, including complex cancers and inherited genetic disorders, which entail the introduction, removal, or modification of genetic material within a patient's cells. Genome editing, particularly through techniques such as CRISPR-Cas9, enables targeted corrections of genetic defects and opens new possibilities for personalized medicine by allowing for precise modifications at the DNA level. The review addresses the ethical implications, clinical applications, and significant advancements of these technologies. This article endeavors to underscore the substantial influence of gene therapy and genome editing on contemporary medicine by assessing the most recent research and clinical trials, thereby emphasizing their potential to revolutionize disease treatment and management.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (1) , 53-66
Gene Therapy and Gene Editing: Current Trends and Future Prospects of Molecular Medicine
Gene therapy and genome editing have emerged as transformative approaches in the management of a diverse range of genetic and acquired diseases. This evaluation offers a thorough examination of the present state and prospects of these innovative technologies. Gene therapy is a prospective approach to the treatment and prevention of a variety of conditions, including complex cancers and inherited genetic disorders, which entail the introduction, removal, or modification of genetic material within a patient's cells. Genome editing, particularly through techniques such as CRISPR-Cas9, enables targeted corrections of genetic defects and opens new possibilities for personalized medicine by allowing for precise modifications at the DNA level. The review addresses the ethical implications, clinical applications, and significant advancements of these technologies. This article endeavors to underscore the substantial influence of gene therapy and genome editing on contemporary medicine by assessing the most recent research and clinical trials, thereby emphasizing their potential to revolutionize disease treatment and management.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 25 (2)
The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges
This article explores the Human Monkeypox Virus (MPV), a contagious virus that causes disease in both vertebrates and insects. It originated in Denmark in 1958 and expanded beyond Africa during the 1970s. The virus was initially detected in the United States in 2003 following the hospitalisation of a toddler who had been bitten by a prairie dog. The article examines the identification of the virus, its categorization into two genetic groups with different levels of harmfulness, and its genetic changes over time due to specific influences. Additionally, it investigates the immunological reaction to MPXV, encompassing both the innate and adaptive systems. This article also addresses the diagnostic difficulties presented by MPXV's resemblance to other orthopoxviruses and the progress made in molecular diagnostics. The paper analyses different therapeutic interventions, such as tecovirimat, an antiviral medication, and JYNNEOS, a vaccine, in terms of their efficacy, potential drawbacks, and the difficulties encountered in managing outbreaks. The future outlook emphasises the necessity of inventive research methodologies, worldwide monitoring, and individualised medical treatments to counteract the dissemination of MPXV and alleviate its consequences on public health.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 25 (2)
The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges
This article explores the Human Monkeypox Virus (MPV), a contagious virus that causes disease in both vertebrates and insects. It originated in Denmark in 1958 and expanded beyond Africa during the 1970s. The virus was initially detected in the United States in 2003 following the hospitalisation of a toddler who had been bitten by a prairie dog. The article examines the identification of the virus, its categorization into two genetic groups with different levels of harmfulness, and its genetic changes over time due to specific influences. Additionally, it investigates the immunological reaction to MPXV, encompassing both the innate and adaptive systems. This article also addresses the diagnostic difficulties presented by MPXV's resemblance to other orthopoxviruses and the progress made in molecular diagnostics. The paper analyses different therapeutic interventions, such as tecovirimat, an antiviral medication, and JYNNEOS, a vaccine, in terms of their efficacy, potential drawbacks, and the difficulties encountered in managing outbreaks. The future outlook emphasises the necessity of inventive research methodologies, worldwide monitoring, and individualised medical treatments to counteract the dissemination of MPXV and alleviate its consequences on public health.
- Open Access
- 11 February 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25
Transporter Associated with Antigen ProcessingProteins (TAP-1 and TAP-2) Gene Expressionof MHC-I Downregulated in Oral SquamousCarcinoma
Background: TAP-1 and TAP-2 are crucial proteins for loading antigenic peptides after proteasome-mediated endogenous processing of the MHC-I (Major Histocompatibility Complex- I) pathway. Our study aimed to explore the Transporter Associated with Antigen Processing proteins (TAP-1 and TAP-2) in oral squamous cell carcinoma and premalignant oral lesions. Methods: We recruited a total of 135 subjects from the outpatient department of the ENT unit of our institute. Real-time Polymerase Chain Reaction (PCR) was used to evaluate the levels of TAP-1 and TAP-2 gene expression in pre-cancerous and oral squamous carcinoma samples. Additionally, we measured the circulating levels of inflammatory markers using an automated biochemistry analyzer. Results: In the current study, we found that the subjects with oral squamous cell carcinoma had lower expressions of the TAP 1 and TAP 2 genes than precancerous oral subjects of OSMF, leukoplakia, and OLP. In oral squamous carcinoma subjects, we found a 1.7- and 2.1-fold change in gene expression of TAP-1 and TAP-2, respectively, compared to control subjects. Furthermore, we observed an increase in levels of metabolic inflammatory biomarkers of CRP, ESR, and ferritin in oral squamous carcinoma subjects compared to premalignant cases and controls, indicating the presence and aggravation of systemic inflammation. Conclusion: The study revealed that subjects with oral squamous cell carcinoma have lower TAP 1 and TAP 2 gene expression than premalignant control subjects, thus affecting MHC-I processing, which ultimately affects the functioning of the immune system. These results have the potential to improve our understanding of disease pathophysiology and provide more targeted treatment options.
- 11 February 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25
Open AccessTransporter Associated with Antigen ProcessingProteins (TAP-1 and TAP-2) Gene Expressionof MHC-I Downregulated in Oral SquamousCarcinoma
Background: TAP-1 and TAP-2 are crucial proteins for loading antigenic peptides after proteasome-mediated endogenous processing of the MHC-I (Major Histocompatibility Complex- I) pathway. Our study aimed to explore the Transporter Associated with Antigen Processing proteins (TAP-1 and TAP-2) in oral squamous cell carcinoma and premalignant oral lesions. Methods: We recruited a total of 135 subjects from the outpatient department of the ENT unit of our institute. Real-time Polymerase Chain Reaction (PCR) was used to evaluate the levels of TAP-1 and TAP-2 gene expression in pre-cancerous and oral squamous carcinoma samples. Additionally, we measured the circulating levels of inflammatory markers using an automated biochemistry analyzer. Results: In the current study, we found that the subjects with oral squamous cell carcinoma had lower expressions of the TAP 1 and TAP 2 genes than precancerous oral subjects of OSMF, leukoplakia, and OLP. In oral squamous carcinoma subjects, we found a 1.7- and 2.1-fold change in gene expression of TAP-1 and TAP-2, respectively, compared to control subjects. Furthermore, we observed an increase in levels of metabolic inflammatory biomarkers of CRP, ESR, and ferritin in oral squamous carcinoma subjects compared to premalignant cases and controls, indicating the presence and aggravation of systemic inflammation. Conclusion: The study revealed that subjects with oral squamous cell carcinoma have lower TAP 1 and TAP 2 gene expression than premalignant control subjects, thus affecting MHC-I processing, which ultimately affects the functioning of the immune system. These results have the potential to improve our understanding of disease pathophysiology and provide more targeted treatment options.
- 1 January 2025
- Published by Springer Nature
- p. 241-285
Repurposing of Antiviral Agents in COVID-19
- Open Access
- 30 December 2024
- Vol. 35 (4) , 265-284
MicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives.
The article provides a thorough and up-to-date analysis of the role that microRNAs (miRNAs) within the realm of cancer therapy, paying specific attention to their diagnostic, prognostic as well as therapeutic capabilities. The miRNAs (small non-coding RNAs) are the current major genes that regulate gene expression. They are a key factor in the genesis of cancer. They are oncogenes, or tumor suppressors that play key functions in the signaling pathway that contribute to the development of cancer. This article focuses on the double importance of microRNAs for cancer oncogenesis. This includes both their ability to inhibit cancer suppressor genes and the stimulation of cancer-causing oncogenes. MicroRNAs have been identified for a long time as biomarkers to help in diagnosing cancer and have distinct signatures specific to different kinds of cancer. There are many detection strategies including RT-qPCR, Next Generation Sequencing (NGS) as well as Microarray Analysis that have been evaluated to prove their effectiveness in aiding the non-invasive diagnosis of cancer. The paper provides an overview of the importance of miRNAs to prognosis, highlighting their ability to forecast tumor progression as well as outcomes for cancer patients. In addition, their therapeutic value remains a subject of research. Research is being conducted in order to investigate miRNA-targeting therapy including antisense oligonucleotides, or small molecules inhibitors as possible treatment options for cancer. These methods could favor more specific and individualized approaches than the current techniques. The article also focuses on the current challenges and future prospects linked to miRNA research and demonstrates the complex biological functions they play as well as clinical applications that require investigation. The review is the source of information for researchers, clinicians and scientists who are interested in advancing studies into cancer research as well as personalized treatments.
- 30 December 2024
- Vol. 35 (4) , 265-284
Open AccessMicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives.
The article provides a thorough and up-to-date analysis of the role that microRNAs (miRNAs) within the realm of cancer therapy, paying specific attention to their diagnostic, prognostic as well as therapeutic capabilities. The miRNAs (small non-coding RNAs) are the current major genes that regulate gene expression. They are a key factor in the genesis of cancer. They are oncogenes, or tumor suppressors that play key functions in the signaling pathway that contribute to the development of cancer. This article focuses on the double importance of microRNAs for cancer oncogenesis. This includes both their ability to inhibit cancer suppressor genes and the stimulation of cancer-causing oncogenes. MicroRNAs have been identified for a long time as biomarkers to help in diagnosing cancer and have distinct signatures specific to different kinds of cancer. There are many detection strategies including RT-qPCR, Next Generation Sequencing (NGS) as well as Microarray Analysis that have been evaluated to prove their effectiveness in aiding the non-invasive diagnosis of cancer. The paper provides an overview of the importance of miRNAs to prognosis, highlighting their ability to forecast tumor progression as well as outcomes for cancer patients. In addition, their therapeutic value remains a subject of research. Research is being conducted in order to investigate miRNA-targeting therapy including antisense oligonucleotides, or small molecules inhibitors as possible treatment options for cancer. These methods could favor more specific and individualized approaches than the current techniques. The article also focuses on the current challenges and future prospects linked to miRNA research and demonstrates the complex biological functions they play as well as clinical applications that require investigation. The review is the source of information for researchers, clinicians and scientists who are interested in advancing studies into cancer research as well as personalized treatments.